Article Text

Download PDFPDF
What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case–control study
  1. K. BM. Lee*,
  2. J. M. Lee,
  3. C. Y. Park*,
  4. K. B. Lee*,
  5. H. Y. Cho and
  6. S. Y. Ha
  1. *Department of Obstetrics and Gynecology, Gachon Medical School Gil Medical Center, Inchon, South Korea
  2. Department of Obstetrics and Gynecology, East-West Neo Medical Center, Kyung Hee University, Seoul, South Korea
  3. Department of Pathology, Gachon Medical School Gil Medical Center, Inchon, South Korea
  1. Address correspondence and reprint requests to: Jong-Min Lee, MD, PhD, Department of Obstetrics and Gynecology, East-West Neo Medical Center, Kyung Hee University, 149 Sangil-dong, Gangdong-gu, Seoul, 134–090, South Korea. Email: kgo02{at}hanmail.net

Abstract

The objective of this study was to investigate the efficacy of treatment strategies in patients with adenocarcinoma (AC) of the cervix and compare it with those with squamous cell carcinoma (SCC) of the cervix. Women with FIGO (1994) stage IB1 AC, especially pathologic tumor size of 2–4 cm, treated with class III hysterectomy, were compared with those with SCC treated with comparable strategy in a case-controlled study. Eighty patients (20 cases, 60 controls) were analyzed. Lymphvascular space invasion (P = 0.01) and lymph node metastasis (P = 0.07) were more frequent in patients with SCC than in those with AC. However, there was no significant difference in depth of stromal invasion (P = 0.51) and invasion of the parametrium (P = 0.44) between two groups. And there was also no statistically significant difference in disease-free survival (P = 0.86) and overall survival (P = 0.89) between two groups. Primary radical surgery followed by adjuvant therapy, same as for SCC, would be acceptable for AC with pathologic tumor size of 2–4 cm. Although it was difficult to determine whether AC recurred more systemically, more effective treatment strategies than those currently available for AC should be considered to reduce the systemic recurrence.

  • adenocarcinoma
  • stage IB1
  • squamous cell carcinoma

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.